UGLK Science AB
559194-2163ActiveDeveloping patented ex-vivo perfusion technology to increase transplantable kidneys globally.
MedTech/Biotechnology Companyuglkscience.com
Overview
- 1–4
- Employees
- 750–999K SEK
- Revenue
- 2019
- Founded
Key Decision Makers
Magnus Nilsson
CEO
@uglkscience.com
Description
UGLK Science AB is a Swedish biotechnology company focused on solving the critical shortage of transplantable donor kidneys. They have developed a patented ex-vivo kidney perfusion system designed for the reconditioning and evaluation of organs. This innovative system comprises a durable perfusion m...
Tags
B2BHealthTech